Group One Trading’s Verve Therapeutics VERV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-71,300
Closed -$801K 9212
2025
Q2
$801K Buy
71,300
+40,400
+131% +$230K ﹤0.01% 2972
2025
Q1
$141K Sell
30,900
-19,800
-39% -$133K ﹤0.01% 4312
2024
Q4
$286K Buy
50,700
+47,300
+1,391% +$267K ﹤0.01% 3631
2024
Q3
$16.5K Sell
3,400
-500
-13% -$2.9K ﹤0.01% 5337
2024
Q2
$19K Sell
3,900
-700
-15% -$4.4K ﹤0.01% 5265
2024
Q1
$61.1K Buy
4,600
+800
+21% +$10.6K ﹤0.01% 4543
2023
Q4
$53K Buy
3,800
+2,700
+245% +$33.5K ﹤0.01% 5011
2023
Q3
$14.6K Sell
1,100
-9,000
-89% -$145K ﹤0.01% 6119
2023
Q2
$189K Sell
10,100
-14,900
-60% -$248K ﹤0.01% 3991
2023
Q1
$361K Buy
25,000
+12,700
+103% +$249K ﹤0.01% 3081
2022
Q4
$238K Buy
12,300
+300
+3% +$7.95K ﹤0.01% 3712
2022
Q3
$412K Buy
12,000
+11,000
+1,100% +$351K ﹤0.01% 3423
2022
Q2
$15K Buy
+1,000
New +$15.5K ﹤0.01% 6524

Other funds holding VERV

Group One Trading's VERV Position: Q3 2025 in Review

Group One Trading sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 45,160 shares — an estimated $507K sold.

Group One Trading first reported a position in VERV in Q4 2022 and held it in 8 quarters. The position peaked at $507K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Group One Trading reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Group One Trading sold 45,160 Verve Therapeutics shares in Q3 2025, an estimated $507K.
  • Group One Trading first reported a position in Verve Therapeutics in Q4 2022 and held it in 8 quarters.
  • Group One Trading's Verve Therapeutics position peaked at $507K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.